A tipping point in drug dosing in late-life schizophrenia

Takashi Tsuboi, Takefumi Suzuki, Hiroyuki Uchida

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Minimally effective doses of antipsychotics are likely influenced by several clinical and demographic characteristics of patients, with age being one of the most important elements. In light of age-related physiologic changes as well as interindividual differences in pharmacokinetic and pharmacodynamic systems, individualized dosing with regard to age will be critically important for safer drug treatment for older patients with schizophrenia. In the present review, we propose the following cautious psychopharmacologic interventions for this population: 1) simple regimen (avoid polypharmacy), 2) be aware of the presence of patients who are very sensitive to drugs, 3) gradual dose titration, and 4) timely and thorough assessments of therapeutic and side effects. The age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients with schizophrenia age to maximize therapeutic effects and minimize side effects.

Original languageEnglish
Pages (from-to)225-233
Number of pages9
JournalCurrent Psychiatry Reports
Volume13
Issue number3
DOIs
Publication statusPublished - 2011 Jun

Fingerprint

Schizophrenia
Antipsychotic Agents
Therapeutic Uses
Pharmaceutical Preparations
Polypharmacy
Pharmacokinetics
Demography
Population
Therapeutics

Keywords

  • Aging
  • Antipsychotics
  • Geriatrics
  • Schizophrenia
  • Sensitivity

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A tipping point in drug dosing in late-life schizophrenia. / Tsuboi, Takashi; Suzuki, Takefumi; Uchida, Hiroyuki.

In: Current Psychiatry Reports, Vol. 13, No. 3, 06.2011, p. 225-233.

Research output: Contribution to journalArticle

Tsuboi, Takashi ; Suzuki, Takefumi ; Uchida, Hiroyuki. / A tipping point in drug dosing in late-life schizophrenia. In: Current Psychiatry Reports. 2011 ; Vol. 13, No. 3. pp. 225-233.
@article{1547239395ad40e6b3e2ed8bb70ac2de,
title = "A tipping point in drug dosing in late-life schizophrenia",
abstract = "Minimally effective doses of antipsychotics are likely influenced by several clinical and demographic characteristics of patients, with age being one of the most important elements. In light of age-related physiologic changes as well as interindividual differences in pharmacokinetic and pharmacodynamic systems, individualized dosing with regard to age will be critically important for safer drug treatment for older patients with schizophrenia. In the present review, we propose the following cautious psychopharmacologic interventions for this population: 1) simple regimen (avoid polypharmacy), 2) be aware of the presence of patients who are very sensitive to drugs, 3) gradual dose titration, and 4) timely and thorough assessments of therapeutic and side effects. The age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients with schizophrenia age to maximize therapeutic effects and minimize side effects.",
keywords = "Aging, Antipsychotics, Geriatrics, Schizophrenia, Sensitivity",
author = "Takashi Tsuboi and Takefumi Suzuki and Hiroyuki Uchida",
year = "2011",
month = "6",
doi = "10.1007/s11920-011-0189-z",
language = "English",
volume = "13",
pages = "225--233",
journal = "Current Psychiatry Reports",
issn = "1523-3812",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - A tipping point in drug dosing in late-life schizophrenia

AU - Tsuboi, Takashi

AU - Suzuki, Takefumi

AU - Uchida, Hiroyuki

PY - 2011/6

Y1 - 2011/6

N2 - Minimally effective doses of antipsychotics are likely influenced by several clinical and demographic characteristics of patients, with age being one of the most important elements. In light of age-related physiologic changes as well as interindividual differences in pharmacokinetic and pharmacodynamic systems, individualized dosing with regard to age will be critically important for safer drug treatment for older patients with schizophrenia. In the present review, we propose the following cautious psychopharmacologic interventions for this population: 1) simple regimen (avoid polypharmacy), 2) be aware of the presence of patients who are very sensitive to drugs, 3) gradual dose titration, and 4) timely and thorough assessments of therapeutic and side effects. The age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients with schizophrenia age to maximize therapeutic effects and minimize side effects.

AB - Minimally effective doses of antipsychotics are likely influenced by several clinical and demographic characteristics of patients, with age being one of the most important elements. In light of age-related physiologic changes as well as interindividual differences in pharmacokinetic and pharmacodynamic systems, individualized dosing with regard to age will be critically important for safer drug treatment for older patients with schizophrenia. In the present review, we propose the following cautious psychopharmacologic interventions for this population: 1) simple regimen (avoid polypharmacy), 2) be aware of the presence of patients who are very sensitive to drugs, 3) gradual dose titration, and 4) timely and thorough assessments of therapeutic and side effects. The age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients with schizophrenia age to maximize therapeutic effects and minimize side effects.

KW - Aging

KW - Antipsychotics

KW - Geriatrics

KW - Schizophrenia

KW - Sensitivity

UR - http://www.scopus.com/inward/record.url?scp=79955894406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955894406&partnerID=8YFLogxK

U2 - 10.1007/s11920-011-0189-z

DO - 10.1007/s11920-011-0189-z

M3 - Article

C2 - 21327902

AN - SCOPUS:79955894406

VL - 13

SP - 225

EP - 233

JO - Current Psychiatry Reports

JF - Current Psychiatry Reports

SN - 1523-3812

IS - 3

ER -